Bafna Pharmaceuticals Posts INR 692.33 Lakh Profit Before Tax in Q2 2026 Unaudited Results
Company reports total income of INR 4,879.97 lakh and shares assets and liabilities details as of September 30, 2026
Bafna Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting profit before tax of INR 692.33 lakh for the quarter. The results include a total income of INR 4,879.97 lakh for the quarter and highlight key financial positions as of September 30, 2026, supported by a limited review report from statutory auditors.
Bafna Pharmaceuticals Limited
Financial Results
Bafna Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, posting a profit before tax of INR 692.33 lakh for the quarter. These results were reviewed by the audit committee and accompanied by a limited review report from the statutory auditors.
The company reported total income for the quarter of INR 4,879.97 lakh, including revenue from operations of INR 4,766.56 lakh and other income of INR 113.41 lakh.
Total expenses for the quarter were INR 4,821.91 lakh, resulting in a profit before exceptional items and tax of INR 7.51 lakh, improving to INR 692.33 lakh after adjustments for costs within the quarter.
As of September 30, 2026, Bafna Pharmaceuticals held total assets valued at INR 19,300.29 lakh, with equity of INR 10,319.44 lakh. Non-current assets mainly consist of property, plant, and equipment valued at INR 8,803.62 lakh.
The company stated ongoing legal matters concerning Goods and Services Tax (GST) claims amounting to INR 566.56 lakh and reported confidence in prevailing against these claims based on current legal positions and practices.
The unaudited results have been prepared according to Indian Accounting Standards (Ind AS 34) and reviewed by the statutory auditors through limited review in compliance with SEBI regulations.
Highlights
- Profit before tax of INR 692.33 lakh reported for quarter ended September 30, 2026.
- Total income for the quarter: INR 4,879.97 lakh.
- Equity share capital remains at INR 2,365.63 lakh with other equity at INR 7,953.81 lakh as of September 30, 2026.
- Total assets recorded at INR 19,300.29 lakh, reflecting the company's financial position at period end.
- Company continuing legal appeals regarding GST liabilities totaling over INR 566 lakh with associated stay orders obtained.
Key Data Snapshot
Financial performance
- The company earned revenue from operations of INR 4,766.56 lakh and other income of INR 113.41 lakh during Q2 2026.
- Total expenses amounted to INR 4,821.91 lakh including costs of materials, manufacturing, employee benefits, finance costs, and depreciation.
- Profit before tax for the quarter was INR 692.33 lakh after accounting for income and expenses.
- Earnings per share (basic and diluted) for the quarter stood at INR 2.89.
- Comprehensive income for the quarter totaled INR 690.90 lakh.
Key details
- Unaudited financial results for Q2 and H1 ended September 30, 2026, approved by the Board on November 11, 2026.
- Results reviewed by the Audit Committee and statutory auditors issued a limited review report.
- Company prepared the results under Ind AS 34 in compliance with Indian accounting standards and SEBI regulations.
- Reported GST-related claims of INR 235.47 lakh and INR 331.09 lakh are under legal appeal or stay, with confidence to prevail against GST authorities.
- Board meeting was held from 2:35 PM to 3:50 PM on November 11, 2026, to approve these results.
Background and context
- Bafna Pharmaceuticals operates in the pharmaceutical formulation manufacturing segment, considered a single business segment under Ind AS 108.
- The company maintains its registered and corporate office in Chennai, India.
- The financial results reflect ongoing business operations including production, sales, and associated costs for the reported periods.
- Company adheres to regulations under SEBI (Listing Obligations and Disclosure Requirements) and Indian Companies Act for disclosures.
Highlights
- Profit before tax of INR 692.33 lakh reported for quarter ended September 30, 2026.
- Total income for the quarter: INR 4,879.97 lakh.
- Equity share capital remains at INR 2,365.63 lakh with other equity at INR 7,953.81 lakh as of September 30, 2026.
- Total assets recorded at INR 19,300.29 lakh, reflecting the company's financial position at period end.
- Company continuing legal appeals regarding GST liabilities totaling over INR 566 lakh with associated stay orders obtained.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 (Ind AS 34)
- Companies Act, 2013
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Kaynes Technology India Limited Reports Q2 FY2027 Un-audited Results and Enters Joint Venture to Produce TFT Modules
Kaynes Technology India Limited released its un-audited financial results for the quarter and half year ended September 30, 2026, and approved a joint venture with Toyokawa Techno Private Limited to produce Thin-Film Transistor Display Modules in India, while proposing voluntary strike-off of a subsidiary.
Read Full StoryITI Limited Reports ₹49,528 Lakh Revenue and ₹6,368 Lakh Consolidated Loss Before Tax for Half Year Ending September 2026
ITI Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended 30th September 2026, revealing total consolidated revenue of ₹49,528 lakh for the quarter and a consolidated loss before tax of ₹6,368 lakh for the half-year period.
Read Full StoryZetwerk Manufacturing Businesses Limited Reports Q2 FY2027 Loss with Rs. 886.06 Million Receivables Dispute, Appoints New Company Secretary
Zetwerk Manufacturing Businesses Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, reporting a loss before tax of Rs. 1,193.17 million for the quarter. The company highlighted ongoing litigation over receivables totaling Rs. 886.06 million, alongside key administrative updates.
Read Full Story